Drug intelligence / Profile preview

BM365

Development stage: Preclinical
Lead developer: Biomissile Pharmaceuticals

Overview

BM365 is an investigational therapeutic candidate being developed by Biomissile for the treatment of autoimmune diseases. It is designed to function through an immune blockade mechanism, intended to inhibit pathogenic immune pathways that drive autoimmune pathology. While the specific molecular target and the exact autoimmune indications have not been publicly disclosed, the drug is part of Biomissile's pipeline of immune-modulating assets aimed at addressing chronic inflammatory and autoimmune conditions.

Beyond the preview

Go deeper on BM365.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BM365.

Explore the full profile